GlassScriptPhysician profile
David W Crumpacker
NPI 1912996562
$386,348.10
in general payments reported to CMS, 2019-2025
42 companies · $51K in 2025
The $51K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $41K · 2021: $35K · 2022: $33K · 2023: $63K · 2024: $121K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Consulting Fee: $45K · Honoraria: $26K · Travel and Lodging: $19K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,292.50 |
| Consulting Fee | $44,625.00 |
| Honoraria | $26,400.00 |
| Travel and Lodging | $19,411.58 |
| Food and Beverage | $13,704.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $77,988.62 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $69,393.86 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $67,398.46 | 2019-2025 | Rexulti, Nuedexta |
| Eisai INC. | $53,394.95 | 2020-2025 | |
| Avanir Pharmaceuticals, INC. | $52,957.78 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $31,809.33 | 2022-2024 | Quviviq |
| Allergan, INC. | $10,127.85 | 2019-2020 | |
| Alkermes, INC. | $7,448.88 | 2021-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $4,622.68 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $3,152.74 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,261.87 | 2021-2025 | Vraylar |
| Validus Pharmaceuticals LLC | $923.72 | 2021-2024 | Equetro |
| Neurocrine Biosciences, INC. | $890.11 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $752.79 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $571.56 | 2020-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $488.29 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $405.15 | 2020-2025 | Caplyta |
| Corium, LLC | $402.55 | 2022-2025 | Azstarys, Adlarity, Azstarys |
| Almatica Pharma LLC | $357.85 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $240.86 | 2022-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $220.84 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $167.78 | 2019-2022 | |
| Noven Therapeutics, LLC | $155.16 | 2021-2025 | Xelstrym, Secuado |
| Novartis Pharmaceuticals Corporation | $148.49 | 2020-2021 | |
| Bausch Health US, LLC | $139.63 | 2021-2025 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $136.49 | 2020-2023 | Belsomra |
| Itamar Medical INC | $126.67 | 2024-2025 | Watchpatone |
| Jazz Pharmaceuticals INC. | $115.97 | 2021-2022 | |
| Adlon Therapeutics L.P. | $81.02 | 2020-2021 | |
| Lilly USA, LLC | $71.09 | 2022-2024 | Amyvid |
| Supernus Pharmaceuticals, INC. | $69.11 | 2021-2023 | Qelbree |
| Biogen, INC. | $68.49 | 2021-2022 | |
| Genzyme Corporation | $49.85 | 2019-2021 | |
| Alfasigma USA, INC. | $37.60 | 2021 | |
| Ge Healthcare | $36.44 | 2019 | |
| Neos Therapeutics, LP | $30.84 | 2021-2024 | Adzenys Xr-Odt |
| Noven Pharmaceuticals, INC. | $23.64 | 2021 | |
| Grt US Holding, INC. | $21.93 | 2019 | |
| Bioxcel Therapeutics, INC. | $18.54 | 2023 | Igalmi |
| Shire North American Group INC | $13.57 | 2019 | |
| Life Molecular Imaging LTD | $12.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crumpacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.